Report of Foreign Issuer (6-k)
July 28 2017 - 7:16AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the Month of July 2017
Commission File Number: 001-36697
DBV
TECHNOLOGIES S.A.
(Translation of registrants name into English)
177-181 avenue Pierre Brossolette
92120 Montrouge France
(Address of principal executive office)
Indicate by check mark whether
the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
☒ Form
20-F ☐ Form 40-F
Indicate by check mark if the registrant is
submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting
the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
EXHIBIT LIST
|
|
|
Exhibit
|
|
Description
|
|
|
99.1
|
|
Press Release dated July 28, 2017.
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
DBV TECHNOLOGIES S.A.
|
|
|
|
|
Date: July 28, 2017
|
|
|
|
By:
|
|
/s/ David Schilansky
|
|
|
|
|
Name
|
|
David Schilansky
|
|
|
|
|
Title:
|
|
Chief Operating Officer
|
Press Release
Montrouge, France, July 28, 2017
DBV
Technologies Reports First Half 2017
Financial Results
DBV
Technologies (Euronext: DBV ISIN: FR0010417345 - Nasdaq Stock Market: DBVT) today reported first half 2017 financial results. The interim financial report is available on the Investor Relations section of the Companys website,
http://www.dbv-technologies.com/en/investor-relations
. First half 2017 financial statements were subject to a limited review by the Companys external auditors.
First Half 2017 Financial Results
Cash Position:
cash and cash equivalents as of June 30, 2017, were 198.7 million, compared to 256.5 million as of December 31, 2016, a decrease of 57.8 million.
Operating Income:
operating income was 7.6 million for the first half 2017 compared to 4.8 million for the prior-year period, an
increase of 60%. In the first half 2017, income was primarily generated by the Companys Research Tax Credit (
Crédit Impôt Recherche
) and by income recognized under the May 2016 collaboration agreement with Nestlé
Health Science.
Research
& Development Expenses:
research and development expenses increased by 19.6 million, or
60%, to 52.5 million in the first half 2017, compared to 32.9 million in the first half 2016, reflecting costs associated with the ongoing Phase III and Phase II clinical trials of Viaskin Peanut and Viaskin Milk, respectively,
as well as a substantial increase in the number of research and development personnel employed by the Company.
Sales
&
Marketing Expenses:
sales and marketing expenses were 8.5 million for the first half 2017 compared to 5.5 million for the first half 2016, reflecting an increase of 3.0 million, or 56%, compared to the prior-year
period. The increase in sales and marketing expenses resulted from an increase in U.S. employee headcount and expenses related to the potential launch and commercialization of Viaskin Peanut in North America.
General
& Administrative Expenses:
general and administrative expenses increased by 1.9 million, or 12%, to
17.7 million for the first half 2017, compared to 15.8 million for the first half 2016. The increase in general and administrative expenses was primarily attributable to an increase in global employee headcount, costs
associated with legal and professional services, NASDAQ-listing expenses, as well as compensation and other personnel expenses. This increase was partially offset by a decrease in insurance expenses following the termination of the
12-month
Public Offering of Security Insurance (POSI) policy related to the Companys July 2015
follow-on
offering.
Net Loss:
net loss was 72.5 million for the first half 2017, compared to
49.4 million for the first half 2016. Loss per share (based on the weighted average number of shares outstanding over the period) was (2.94) and (2.03) for the first half 2017 and 2016, respectively.
About DBV Technologies
DBV Technologies is developing
Viaskin
®
, a proprietary technology platform with broad potential applications in immunotherapy. Viaskin is based on epicutaneous immunotherapy, or EPIT
®
, DBVs method of delivering biologically active compounds to the immune system through intact skin. With this new class of self-administered and
non-invasive
product candidates, the company is dedicated to safely transforming the care of food allergic patients, for whom there are no approved treatments. DBVs food allergies programs include
ongoing clinical trials of Viaskin Peanut and Viaskin Milk, and preclinical development of Viaskin Egg. DBV is also pursuing a human
proof-of-concept
clinical study of
Viaskin Milk for the treatment of Eosinophilic Esophagitis, and exploring potential applications of its platform in vaccines and other immune diseases.
DBV Technologies has global headquarters in Montrouge, France and New York, NY. Company shares are traded on segment A of Euronext Paris (Ticker: DBV, ISIN
code: FR0010417345), part of the SBF120 index, and traded on the Nasdaq Global Select Market in the form of American Depositary Shares (each representing
one-half
of one ordinary share) (Ticker: DBVT). For
more information on DBV Technologies, please visit our website:
www.dbv-technologies.com
DBV
Technologies Contact
Sara Blum Sherman
Director,
Investor Relations
+1 212-271-0740
sara.sherman@dbv-technologies.com
Media Contact
Andrea Fassacesia, Weber Shandwick
+1 212-445-8144
afassacesia@webershandwick.com
Media Contact Europe
Caroline Carmagnol, Alize RP,
Relations Presse
+33 (0)6 64 18 99 59
caroline@alizerp.com
DBV Technologies (NASDAQ:DBVT)
Historical Stock Chart
From Aug 2024 to Sep 2024
DBV Technologies (NASDAQ:DBVT)
Historical Stock Chart
From Sep 2023 to Sep 2024